Evolus, Inc (EOLS)

Etorro trading 970x250
Evolus, Inc (EOLS) Logo

About Evolus, Inc

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California. Address: 520 Newport Center Drive, Newport Beach, CA, United States, 92660

Evolus, Inc News and around…

Latest news about Evolus, Inc (EOLS) common stock and company :

Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2022
20 Jan, 2022 FinancialContent

Upgrades For W.P. Carey Inc (NYSE:WPC), B of A Securities upgraded the previous rating of Underperform to Neutral. W.P. Carey ...

HealthInvest Partners AB Buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Sells ...
18 Jan, 2022 Yahoo! Finance

Stockholm, V7, based Investment company HealthInvest Partners AB (Current Portfolio) buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Bristol-Myers Squibb Co, AbbVie Inc, sells Supernus Pharmaceuticals Inc, Accuray Inc, Aldeyra Therapeutics Inc, Rigel Pharmaceuticals Inc, Evolus Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, HealthInvest Partners AB.

Top Pharmaceutical Stocks for Q1 2022
13 Jan, 2022 Yahoo! Finance

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2022.

Evolus Expands Board of Directors With Appointment of Digital and Beauty Innovator Brady Stewart
05 Jan, 2022 FinancialContent

Evolus announces that it has further strengthened and diversified its Board of Directors with the appointment of Brady Stewart.

Tenaya Therapeutics Appoints Karah Parschauer, J.D., to Its Board of Directors and Joanna Auch as Senior Vice President of People and Culture
22 Dec, 2021 FinancialContent

Tenaya Therapeutics, Inc. announces the appointments of Karah Parschauer to its Board of Directors and of Joanna Auch as SVP of People and Culture.

Evolus Joins Nasdaq Biotechnology Index
20 Dec, 2021 FinancialContent

Evolus announces that its common stock has been selected for inclusion in the Nasdaq Biotechnology Index effective today.

Evolus Enters Into $125 Million Credit Facility with Pharmakon Advisors
14 Dec, 2021 FinancialContent

Evolus, a performance beauty company, has entered into a $125 million term loan financing facility with funds managed by Pharmakon Advisors, L.P.

Evolus Announces Participation in November Investment Conferences
09 Nov, 2021 Yahoo! Finance

NEWPORT BEACH, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in two investment conferences in November. Event:Stifel 2021 Virtual Healthcare Conference Date:Tuesday, November 16, 2021 Time:2:40 pm ET Event:Evercore ISI 4th Annual HealthCONx Virtual Conference Date:Tuesday, November 30, 2021 Ti

Is Evolus (NASDAQ:EOLS) A Risky Investment?
07 Nov, 2021 Yahoo! Finance

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Evolus, Inc. (EOLS) Reports Q3 Loss, Lags Revenue Estimates
02 Nov, 2021 Yahoo! Finance

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of 18.75% and -1.08%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Evolus Reports Third Quarter 2021 Results and Provides Business Update
02 Nov, 2021 Yahoo! Finance

Record Quarter: U.S. Net Revenue Grew 58% Year-over-Year to $26.7 Million $107.8 Million Cash Position at Quarter-EndInitiated Jeuveau® “Extra Strength” Phase II Clinical Program to Demonstrate Extended Duration NEWPORT BEACH, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the third quarter ended September 30, 2021 and provided a

Evolus Initiates Phase II Program with “Extra Strength” Dose for Extended Duration
02 Nov, 2021 Yahoo! Finance

Program Designed to Offer Consumers an “Extra Strength” Dosing OptionEvolus is Uniquely Positioned to Capitalize on this Opportunity with the Company’s Aesthetics-Only Strategy and Jeuveau® Product PrecisionFirst Patient Enrollment Expected in Q1 2022; Expected Completion in 1H 2023 NEWPORT BEACH, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it

Evolus Announces Appointment of Jessica Novak as Senior Vice President, Human Resources
01 Nov, 2021 Yahoo! Finance

NEWPORT BEACH, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that Jessica Novak, SPHR has joined the company as Senior Vice President, Human Resources where she will oversee global efforts to expand, retain and develop an entrepreneurial team bringing innovative products and marketing solutions to the aesthetics industry. “One of Evolus’ greatest ass

Evolus, Inc. (EOLS) Expected to Beat Earnings Estimates: Should You Buy?
26 Oct, 2021 Yahoo! Finance

Evolus, Inc. (EOLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Evolus to Report Third Quarter 2021 Results and Provide Business Update
22 Oct, 2021 Yahoo! Finance

NEWPORT BEACH, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its third quarter 2021 financial results and provide a business update on Tuesday, November 2, 2021, prior to the open of the U.S. financial markets. Management will host a conference call and live webcast to discuss Evolus’ financial results at 9:00 a.m. ET that same da

Relative Strength Alert For Evolus
04 Oct, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Interesting EOLS Put And Call Options For April 2022
29 Sep, 2021 FinancialContent

Investors in Evolus Inc (EOLS) saw new options become available this week, for the April 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 197 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

What Kind Of Shareholders Own Evolus, Inc. (NASDAQ:EOLS)?
23 Sep, 2021 Yahoo! Finance

If you want to know who really controls Evolus, Inc. ( NASDAQ:EOLS ), then you'll have to look at the makeup of its...

Evolus Announces Participation in September Investment Conferences
02 Sep, 2021 FinancialContent
4 Stocks Insiders Are Buying
26 Aug, 2021 FinancialContent

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. ...

12 Health Care Stocks Moving In Monday's After-Market Session
23 Aug, 2021 FinancialContent

Gainers Cara Therapeutics (NASDAQ:CARA) stock rose 22.54% to $17.5 during Monday's after-market session. Trading volume for this ...

When Will Evolus, Inc. (NASDAQ:EOLS) Become Profitable?
09 Aug, 2021 Yahoo! Finance

Evolus, Inc. ( NASDAQ:EOLS ) is possibly approaching a major achievement in its business, so we would like to shine...

First Week of September 17th Options Trading For Evolus
05 Aug, 2021 FinancialContent

Investors in Evolus Inc (EOLS) saw new options begin trading this week, for the September 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EOLS options chain for the new September 17th contracts and identified one put and one call contract of particular interest.

Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
04 Aug, 2021 Yahoo! Finance

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -12.50% and 2.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Evolus Reports Second Quarter 2021 Results and Provides Business Update
04 Aug, 2021 FinancialContent
Sum Up The Parts: DWAS Could Be Worth $96
03 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco DWA SmallCap Momentum ETF (DWAS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $96.40 per unit.

Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
28 Jul, 2021 Yahoo! Finance

Evolus, Inc. (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Evolus to Report Second Quarter 2021 Results and Provide Business Update
22 Jul, 2021 FinancialContent
Can Evolus Disrupt the Botox Market?
03 Jul, 2021 FinancialContent

This small-cap stock is going after a billion-dollar market.

Evolus Announces Appointment of David K. Erickson as Vice President, Investor Relations
30 Jun, 2021 FinancialContent

Evolus, Inc (EOLS) is a NASDAQ Common Stock listed in , ,

970x250